GlaxoSmithKline has begun a groundbreaking effort to boost sales and expand treatment in the developing world by selling medicines to patients at different prices linked to their ability to pay.

The UK-based pharmaceutical group has launched experiments to extend its practice of differential or “tiered pricing” by offering its medicines at variable prices within, as well as between, middle-income countries.